Repatha, a PCSK9 inhibitor used to lower cholesterol, is not yet available in generic form. As of November 2023, there are no approved generic versions of Repatha on the market [1].
When can you expect generic Repatha?
The patent and exclusivity landscape for Repatha is complex. DrugPatentWatch.com tracks these details, but exact generic entry dates can be influenced by litigation and regulatory reviews [2]. Generally, a drug's patent protection needs to expire, and then regulatory bodies must approve generic versions before they can be manufactured and sold.
Why isn't there a generic Repatha yet?
The development and approval of a generic drug require significant time and investment. Generic manufacturers must demonstrate that their product is bioequivalent to the brand-name drug and meet all regulatory standards. For biologics like Repatha, this process can be more intricate than for small-molecule drugs, often involving biosimilar pathways rather than traditional generic ones [3].
What are the alternatives to Repatha?
Besides Repatha, other PCSK9 inhibitors are available, such as Praluent (alirocumab) [4]. These medications work similarly by inhibiting the PCSK9 protein, which helps the liver remove LDL cholesterol from the blood. For patients seeking cholesterol-lowering options, statins remain a primary treatment, and other cholesterol-modifying drugs are also available [5].
How much does Repatha cost?
Repatha is a high-cost medication. The exact out-of-pocket cost for patients can vary significantly based on insurance coverage, pharmacy, and any available patient assistance programs from the manufacturer [6]. Generic availability typically leads to lower drug prices, but this has not yet occurred for Repatha.
Who makes Repatha?
Repatha is manufactured by Amgen Inc. [1].
What are the risks associated with Repatha?
Common side effects reported for Repatha include nasopharyngitis (cold-like symptoms), upper respiratory tract infection, influenza, and reactions at the injection site [1]. It is crucial for patients to discuss potential risks and benefits with their healthcare provider.
Where can I find more information about drug patents?
DrugPatentWatch.com provides detailed information on drug patents, exclusivity periods, and potential generic or biosimilar entry dates for various medications [2].
What is a PCSK9 inhibitor?
PCSK9 inhibitors are a class of injectable medications designed to significantly lower LDL ("bad") cholesterol levels. They work by blocking the PCSK9 protein, which prevents LDL cholesterol from being removed from the bloodstream, thereby increasing the number of LDL receptors on the liver and enhancing cholesterol clearance [7].
Sources:
[1] Repatha. Amgen. https://www.repatha.com/
[2] DrugPatentWatch.com. https://www.drugpatentwatch.com/
[3] Biosimilars. U.S. Food & Drug Administration. https://www.fda.gov/drugs/biosimilars/biosimilars
[4] Praluent Prescribing Information. Regeneron Pharmaceuticals, Inc.
[5] Cholesterol-Lowering Medications. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health-topics/cholesterol-lowering-medications
[6] Repatha Cost and Savings Programs. Amgen. https://www.repatha.com/cost-and-savings
[7] PCSK9 Inhibitors. American Heart Association. https://www.heart.org/en/health-topics/cholesterol/treatment-and-prevention-of-high-cholesterol/pcsk9-inhibitors